Oxaloacetate Shows Promise for Cancer-Related Cognitive Impairment

A new study offers hope for breast cancer survivors struggling with cancer-related cognitive impairment, commonly called chemo brain. The preliminary trial found that eight weeks of treatment with the supplement oxaloacetate led to dramatic and universal improvements in cognitive function, fatigue, and physical functioning among participants.

All 16 evaluable patients in the single-arm study had statistically significant and clinically meaningful improvement on a standardized assessment of perceived cognitive function. The mean score on the FACT-Cog PCI scale nearly doubled, moving from an impaired baseline of 29.1 to a normal range score of 55.5 after eight weeks. Neuropsychological testing also showed gains in executive function and processing speed. Improvements were evident after four weeks and generally increased through the remainder of the study. Fatigue and physical functioning improved significantly, and a trend toward reduced insomnia was observed.

The study, led by Patricia Ganz, MD, of UCLA Health, enrolled 18 women with early-stage breast cancer who were one to five years post-treatment and had moderately severe cognitive impairment. All participants took 500 mg of oxaloacetate orally twice daily for eight weeks.

Safety Profile and Participant Experience

The intervention was generally well tolerated. No serious adverse events occurred during the study. The most commonly reported side effects were gastrointestinal, including indigestion, bloating, constipation, diarrhea, and nausea. These symptoms led two participants to discontinue the trial, while 16 completed the full eight-week course.

Limitations of Current Evidence

Researchers acknowledge the study's limitations. As a preliminary single-arm clinical study without a placebo control group, causality cannot be definitively established. The investigators approached the work with skepticism. The impressive and universal improvements in the first nine participants encouraged them to redesign the study to complete it with a smaller sample and hasten development of a more rigorous trial.

Oxaloacetate is a natural human metabolite central to cellular energy production. It may regulate glutamate metabolism to reduce neuroinflammation, a process potentially stimulated by chemotherapy and radiotherapy. Evidence linking oxaloacetate to cognitive function, along with a lack of pharmacologic interventions for cancer-related cognitive impairment, provided the rationale for the study. The condition is especially prevalent in breast cancer survivors but is not limited to them.

Next Steps in Clinical Development

To confirm these promising early results, researchers plan a larger phase II placebo-controlled trial. This study will enroll 120 participants and test two oxaloacetate doses against a placebo. Enrollment is expected to begin before the end of the year.

Patricia Ganz, MD, said, "These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment." Halle Moore, MD, of the Cleveland Clinic, who was not involved in the study, noted, "They had impressive improvement in patient-perceived cognitive function measures and improvement in fatigue and physical functioning." The follow-on trial is expected to yield definitive results within approximately two years.